大摩:予联邦制药(03933)“与大市同步”评级 目标价升至4.5港元
大摩发布研究报告称,予联邦制药(03933)“与大市同步”评级,目标价由4港元上调12.5%至4.5港元。据下半年的业绩结果更新模型,上调2022-25年每股盈利预测8.6%-14.9%,以反映出销量增长推动胰岛素兽药销量增长;鉴于价格持续上涨,中间体和原料药销售额较高,以及根据2021年的趋势降低运营成本。
文章内容来源于网络,如有侵权,请联系客服删除处理!
Statement:
The content of this article does not represent the views of fxgecko website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!